The emerging antibody markets - Toronto

The emerging antibody markets

Monoclonal and polyclonal antibodies are antigen-specific targeting proteins. Due to their high specificity and selectivity, antibodies have always been used as outstanding tools for biomedical research and essential components of many diagnostics and therapeutics.

The global market for antibodies used in the research was estimated at about $2.3 billion in 2016 and is expected to reach $3.0 billion in 2022. Antibody-based drug discovery and development increased government and industry funding in new discoveries in “hot” research areas such as stem cell research, neuroscience, and cancer research, as well as other key drivers, will bring about an estimated annual growth rate of 4.8%.

Since the commercialization of the first therapeutic monoclonal antibody product in 1986, this class of biopharmaceutical products has been growing rapidly. More than 80 monoclonal antibody products have been approved in the US or other countries for the treatment of a variety of diseases. The combined worldwide sales have increased from $50 billion to $106 billion in 7 years since 2011.

Anogen has been in the antibody industry for 30 years

Anogen Yes Biotech Laboratories Ltd., a Canadian biotech company located in the Greater Toronto Area, has been producing antibody products for research, diagnostic and therapeutic applications for thirty years.

Anogen is a recognized leader worldwide in the biotech industry in the research & development of antibody-based products. Half of the top research antibody suppliers sell Anogen’s products. In the therapeutic antibody research field, Anogen has also been a reliable provider for many companies specialized in pharmaceutics and diagnostics.

Anogen has been ISO certified for 19 years to ensure that customers are provided with products and services of the highest quality.

Anogen has expanded the business to the Chinese market since 2006 and has invested in a number of promising antibody research projects by establishing new branches.

Anogen has a professional team and well-developed antibody research and manufacturing technology platform. All key members hold at least a Master’s degree and one-third of them have a Doctor’s degree. The founder of Anogen, Dr. Ye, is one of the leaders in cancer immunotherapy. The CSO Dr. Wang and Dr. Xu had been working as senior scientists at NIH USA for decades and have published hundreds of papers in the immunology research field.

Anogen has developed antibody products for various applications

Anogen has developed a cell bank of more than 1000 hybridomas, which can be cultured in vitro indefinitely, allowing relatively easy purification of large quantities of monoclonal antibodies. Based on this cell bank, Anogen has marketed more than 300 research antibodies and 60 ELISA kits. More than ten new products are launched every year.

As a research-focused company, Anogen also developed antibody-based diagnostics and therapeutics, including ABCREAM, an effective topical formulation of anti-IL-8 (CXCL8) monoclonal antibody for psoriatic skin, and neonatal TSH ELISA Kit, a diagnostic product used for quantitative measurement of TSH, licensed by Health Canada.

Anogen has a long-term collaborative history with major clinical research institutions and universities across North America and Europe. Anogen has also started new projects to develop laboratory-developed tests (LDT) and personalized cancer treatment, which Anogen believes are creative and important pathways for antibodies for clinical use.

Anogen’s research focuses on three main fields:

• Cytokine Storm Therapy: Antibodies can bind and remove excessive inflammatory cytokines released during trauma, transplant rejection, and acute infection.
• Alzheimer’s Disease (AD): Use an antibody to lower Aβ42 peptide levels in AD patients to improve cognitive deficits.
• Cancer Immunotherapy: Personalized treatment for various cancers.

There are nine projects in Anogen’s pipeline:

Anogen has developed dozens of mAbs with high specificity and selectivity that demonstrate great potential to be developed into novel antibody-based products as diagnostics and therapeutics

• mAbs against IL-8 and MCP-1for SARS/ARDS
• ABCREAM registration in the U.S and Europe market
• mAb against IL-17A for psoriasis treatment
• Skincare product using mAbs anti-IL-8 and TNF-α for allergic skin ailments
• Mabs against Aβ42 and Tau for AD prevention
• PD-1 and PD-L1 checkpoint inhibitors for personalized cancer treatment
• Research on cytokines in the tumor microenvironment for cancer diagnosis and treatment
• CD47 for personalized cancer treatment
• Immunoglobulin Y (IgY) in treating Helicobacter pylori infection

Anogen is a great opportunity to invest in the emerging antibody industry(Phase one of personalized diagnosis and treatment for cytokine storm)

Anogen is seeking to raise funds to accelerate its research projects and collaboration with partners to increase brand awareness and market share.